Werewolf Therapeutics stock analysis
Want to see HOWL full AI Analyst Report?
Werewolf Therapeutics (HOWL) Stock Price & Analysis
HOWL Stock Chart & Stats
- Day’s Range
- $0.98 - $1.15
- 52-Week Range
- $0.27 - $1.20
- Previous Close
- $1.05
- Volume
- N/A
- Average Volume (3M)
- 448.82K
- Market Cap
- $51.03M
- Enterprise Value
- $2.95M
- Total Cash (Recent Filing)
- $41.87M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 1.42
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margins
An approximately 86% gross margin indicates attractive economics on recognized revenue and provides substantial room to fund operating investment if commercial or partnered revenue expands. This gross-profit profile is a durable strength, although it has not yet offset the company’s substantial research and development costs.
Clinical Validation
Clinical responses across multiple solid-tumor settings, together with increased T-cell activation and FDA alignment on the recommended Phase 2 dose, strengthen the platform’s development credibility. These data may support broader clinical advancement and partnering potential over the next several quarters.
Extended Funding Runway
The committed financing materially extends the projected cash runway and should allow the combined company to pursue major clinical and regulatory milestones without relying immediately on additional capital. Greater funding visibility supports continued program execution and reduces near-term financing pressure.
Bears Say
Persistent Unprofitability
Deep operating and net losses show that the current business does not yet convert its strong gross margin into sustainable earnings. Continued investment may be necessary before profitability, leaving results sensitive to clinical spending levels and making the path to durable self-funded operations uncertain.
Ongoing Cash Burn
Negative operating and free cash flow indicate that the company continues consuming cash to operate and advance its pipeline. The deterioration in free cash flow versus the prior comparable measure increases dependence on financing, transactions, or future partnering proceeds to sustain development.
Reduced Equity Base
The sharp multi-year reduction in equity reflects the cumulative effect of sustained losses and weakens balance-sheet durability. Even with zero total debt in the latest period, a much smaller equity base provides less financial resilience and leaves less capacity to absorb setbacks or fund programs internally.
Werewolf Therapeutics News
Werewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat Cancers
Werewolf Therapeutics, Inc. ($HOWL) announced an update on their ongoing clinical study. Werewolf Therapeutics, Inc. (HOWL) has completed a Phase I/Ib study titled “A Multicenter Phase I/Ib Dose Escalation and
Werewolf Therapeutics, Ambros Therapeutics to combine in all-stock transaction
Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing
Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price
Werewolf Therapeutics, Inc. (HOWL) has disclosed a new risk, in the Share Price & Shareholder Rights category. Werewolf Therapeutics, Inc. faces a significant listing risk after receiving a Nasdaq deficiency
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
What is Werewolf Therapeutics’s market cap?
When is Werewolf Therapeutics’s upcoming earnings report date?
How were Werewolf Therapeutics’s earnings last quarter?
Is Werewolf Therapeutics overvalued?
Does Werewolf Therapeutics pay dividends?
What is Werewolf Therapeutics’s EPS estimate?
How many shares outstanding does Werewolf Therapeutics have?
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Werewolf Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Werewolf Therapeutics Stock Smart Score
Company Description
Werewolf Therapeutics
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel J. Hicklin
- Employees
- 39
- Website
- werewolftx.com
- Address
- 200 Talcott Ave, Watertown, MA, 02472, US
Werewolf Therapeutics (HOWL) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 6 | 1 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 12 | 0 | 0 |













